UK markets closed
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • FTSE 250

    20,051.48
    -104.32 (-0.52%)
     
  • AIM

    920.38
    -2.34 (-0.25%)
     
  • GBP/EUR

    1.1851
    -0.0010 (-0.09%)
     
  • GBP/USD

    1.2071
    -0.0088 (-0.72%)
     
  • BTC-GBP

    19,249.70
    -16.95 (-0.09%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • DOW

    32,803.47
    +76.67 (+0.23%)
     
  • CRUDE OIL

    88.53
    -0.01 (-0.01%)
     
  • GOLD FUTURES

    1,792.40
    -14.50 (-0.80%)
     
  • NIKKEI 225

    28,175.87
    +243.67 (+0.87%)
     
  • HANG SENG

    20,201.94
    +27.94 (+0.14%)
     
  • DAX

    13,573.93
    -88.77 (-0.65%)
     
  • CAC 40

    6,472.35
    -41.04 (-0.63%)
     

Defence Therapeutics Inc.: BREAKTHROUGH DISCOVERY: ACCUTOXTM EFFECTIVELY KILLS CANCER CELLS BY DIRECTLY ELICITING DNA DAMAGE

  • Oops!
    Something went wrong.
    Please try again later.
·5-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
Defence Therapeutics Inc.: BREAKTHROUGH DISCOVERY: ACCUTOXTM EFFECTIVELY KILLS CANCER CELLS BY DIRECTLY ELICITING DNA DAMAGE
02.08.2022 / 08:00
The issuer is solely responsible for the content of this announcement.

 

_________________________________________________________________

CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE

 

 

BREAKTHROUGH DISCOVERY: ACCUTOXTM EFFECTIVELY KILLS CANCER CELLS BY DIRECTLY ELICITING DNA DAMAGE

 

Vancouver, BC, Canada, August 2nd, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells.

 

Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly due to losses in the ability of a given cell to activate its own cell death via a specific set of proteins known to sense unusual activities. Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this.

 

Defence previously reported (see press release of June 22, 2021) the discovery of an AccumTM variant, AccuTOXTM, capable of controlling cancer growth when injected directly in tumors. The use of AccuTOXTM in combination with multiple immune-checkpoints results in a survival rate between 60% and 100%, based on the pre-clinical tumor models studies in mice. The mode of action of AccuTOXTM approached is a non-biased transcriptomic application and revealed that the compound impairs several crucial pathways including DNA replication, cell division, nuclear integrity, and multiple modifications affecting DNA activity. The accumulation of exhaustive cell repair mechanisms triggered by AccuTOXTM combined to the build-up of misfolded proteins and generation of free radicals induce irreversible DNA damages leading to a general collapse in several cellular pathways resulting in effective cancer cell death.

 

"Defence’s breakthrough discovery with its AccuTOXTM formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with AccumTM. Discovering that AccuTOXTM can behave as a chemotherapeutic agent targeting the DNA of cancer cells and an immune-checkpoint inhibitor booster is a new discovery that is highly valuable to Defence’s pipeline and future potential developments. The AccuTOXTM presents a novel discovery as a platform for targeting multiple cancers. This novel discovery creates significant values and applications to our Antibody Drug Conjugate (“ADC”) pipeline. Results are convincing that AccuTOXTM is the perfect potent small molecule to use in the development of our own ADC", says Mr. Plouffe, the CEO of Defence Therapeutics.

 

Defence is currently conducting GLP studies on AccuTOXTM prior to initiate a Phase I trial in North America.

 

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

 

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

 

Cautionary Statement Regarding “Forward-Looking” Information

 

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

 

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

 

 


02.08.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Defence Therapeutics Inc.

1680 - 200 Burrard St

V6C3L6 Vancouver

Canada

E-mail:

info@defencetherapeutics.com

Internet:

https://defencetherapeutics.com

ISIN:

CA24463V1013

WKN:

A3CN14

Listed:

Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto

EQS News ID:

1410883


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting